Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 13/20 | 0.72 |
| ▸ | HTR1A | P08908 | 3/20 | 0.67 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29877197 | 0.86 | HTR7 (0.72) | HTR7HTR1AP2RX7LMNADRD2 | |
| SCHEMBL8136027 | 0.86 | HTR7 (0.72) | HTR7HTR1AP2RX7LMNA | |
| SCHEMBL27246583 | 0.84 | HTR7 (0.68) | HTR7HTR1AP2RX7LMNADRD2 | |
| SCHEMBL8120775 | 0.83 | HTR7 (0.69) | HTR7HTR1AP2RX7LMNADRD2 | |
| SCHEMBL8131304 | 0.82 | HTR7 (1.00) | HTR7HTR1ADRD2 | |
| SCHEMBL8135691 | 0.82 | HTR7 (1.00) | HTR7HTR1AP2RX7LMNADRD2 | |
| SCHEMBL27031067 | 0.81 | HTR7 (0.76) | HTR7HTR1AP2RX7LMNADRD2 | |
| SCHEMBL29876367 | 0.81 | HTR7 (0.73) | HTR7HTR1AP2RX7LMNADRD2 | |
| SCHEMBL27031059 | 0.81 | HTR7 (0.84) | HTR7HTR1AP2RX7LMNADRD2 | |
| SCHEMBL8128438 | 0.80 | HTR7 (1.00) | HTR7HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199555-A1 | APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HT7 RECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION | Université d'Orléans (FR) | 2024-06-20 | — | — | US | disclosed |
| EP-4308119-A1 | <SUP2/>? <SUB2/>?7?APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HTRECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION | Centre National de la Recherche Scientifique (FR) | 2024-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199555-A1 | APPLICATIONS OF BIASED LIGANDS OF THE SEROTONIN 5-HT7 RECEPTOR FOR THE TREATMENT OF PAIN, MULTIPLE SCLEROSIS AND THE CONTROL OF THERMOREGULATION | HTR7, HTR1A, CNR1 | HTR7 1/4885HTR1A 2/4885P2RX7 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.